Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may present risk to patients treated with donor-derived microbiome therapies when appropriate manufacturing controls and inactivation processes are lacking. We report that the manufacturing steps for SER-109, a purified investigational mic...

Descripción completa

Detalles Bibliográficos
Autores principales: McChalicher, Christopher, Abdulaziz, Ahmad, Zhou, S Steve, Lombardo, Mary-Jane, Hasson, Brooke, Auniņš, John G, McGovern, Barbara H, Ege, David S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492665/
https://www.ncbi.nlm.nih.gov/pubmed/36158136
http://dx.doi.org/10.1093/ofid/ofac448

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492665/
https://www.ncbi.nlm.nih.gov/pubmed/36158136
http://dx.doi.org/10.1093/ofid/ofac448

Ejemplares similares